gastroenterological cancer
Conditions
Interventions
None listed
Sponsors
Hokkaido Gastrointestinal Cancer Study Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients who are treated with chemotherapy in gastroenterological cancer. 2.Age <=20 years old at the time of registration. 3.Patients with ECOG Performance Status (PS) 0-2. 4.Patients whose dysgeusia is Grade 1 or higher according to Common Terminology Criteria for Adverse Events v5.0 (CTCAE v5.0) or Grade 1 or higher according to Scale of Subjective Total Taste Acuity (STTA), and who has not been treated for dysgeusia. 5.Patients who are denied other diseases that cause taste disorder. 6.Patients expected to survive for at least 12 weeks from the date of registration. 7.Patients who can take orally. 8.Patients who have given written informed consent to participate in the study.
Exclusion criteria
Exclusion criteria: 1.Patients with serious complications (heart failure, liver failure, renal failure, active gastrointestinal ulcer, intestinal paralysis, etc.) 2.Patients with clinically significant mental or central nervous system disorders. 3.Patients with a history of head and neck radiation therapy. 4.Women who are pregnant or may become pregnant. Lactating woman. 5.Patients already taking zinc-containing preparations (including supplements) 6.Patients who are allergic to zinc-containing preparations. 7.Patients planning to finish chemotherapy within 12 weeks. 8.Patients whose physician predicts that it is difficult to continue chemotherapy for more than 12 weeks. 9.Participation in the clinical trial is determined as unsuitable.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in taste disorders | — |
Secondary
| Measure | Time frame |
|---|---|
| Relationship between serum zinc level and taste disorder, involvement of physical factors (age, height, weight, body surface area), involvement of nutritional factors (hemoglobin level, serum iron, albumin level), safety of drugs used | — |
Countries
Japan
Contacts
Public ContactKen Ito
Hokkaido University Hospital Cancer Center
Outcome results
None listed